Why the study?
Diabetic nephropathy is a major complication of type 2 diabetes mellitus, prompting investigation into the effects of angiotensinogen M235T/T174M and angiotensin type 1 receptor A1166C gene polymorphisms on its development.
Are angiotensinogen M235T/T174M and angiotensin type 1 receptor A1166C gene polymorphisms associated with the development of diabetic nephropathy in type 2 diabetes mellitus patients?
Are angiotensinogen M235T/T174M and angiotensin type 1 receptor A1166C gene polymorphisms associated with the development of diabetic nephropathy in type 2 diabetes mellitus patients?
Angiotensinogen M235T/T174M and angiotensin type 1 receptor A1166C gene polymorphisms are not significantly associated with the development of diabetic nephropathy in patients with type 2 diabetes mellitus.
Answers are grounded in this paper and cite their sources.
These polymorphisms may associate with nephropathy risk; leaves open clinical utility pending larger replication.
AIMS: Diabetic nephropathy is one of the major complications of Type 2 diabetes mellitus. In this study, we aimed to investigate the effects of angiotensinogen M235T/T174M and angiotensin type 1 receptor A1166C gene polymorphisms on the development of diabetic nephropathy in patients with type 2 diabetes mellitus. METHODS: This study included 100 type‑2 diabetes mellitus patients with diabetic nephropathy patients (patient group) and 99 type‑2 diabetes mellitus patients without diabetic nephropathy (control group). Polymerase chain reaction and restriction fragment length polymorphism methods were used to identify polymorphisms in the angiotensinogen M235T/T174M and angiotensin type 1 receptor A1166C genes. RESULTS: There was no significant difference in genotype frequencies of M235T gene polymorphism between patient and control groups (χ2 = 4.01, df = 2, p = 0.13). There was no significant difference in genotype frequencies of T174M gene polymorphism between patient and control groups (X2 = 0.36, df = 2, p = 0.83). There was no significant difference in genotype frequencies of A1166C gene polymorphism between patient and control groups (χ2 = 0.51, df = 2, p = 0.77). CONCLUSIONS: The results showed no significant difference in angiotensinogen M235T/T174M and angiotensin type 1 receptor A1166C gene polymorphisms between the patient and control groups. Future studies are needed to validate the results of this study and to explore underlying mechanisms (Tab. 3, Fig. 3, Ref. 35). Text in PDF www.elis.sk Keywords: type 2 diabetes mellitus, diabetic nephropathy, angiotensinogen gene polymorphism, angiotensin type 1 receptor, gene polymorphism.
No takes yet. Share an insight, caveat, or question.
Yükçü et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: